Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other non-Hodgkin’s B-cell lymphomas - a phase 2 study

Data presented during the 2021 European Hematology Association Virtual Congress appears to show that CD37-targeting antibody naratuximab emtansine is both safe and effective for the treatment of DLBCL and other non-Hodgkin B-cell lymphomas. At a median of 15 months, the overall response rate was 44.7%, and 24 (31.6%) patients had a complete response. Eighty-one percent of patients experienced a grade 3 or worse treatment-related adverse event.